Pulse Biosciences Inc (NAS:PLSE)

Q2 2026 Pulse Biosciences Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: $38.24 (+0.90%)

Transcript 10-Q8-K

Key Points

Positve

Pulse Biosciences Inc (PLSE) reported exceptional enrollment progress in its pivotal NanoPulse-AF IDE study, surpassing the halfway point with over 82 patients and confirming an accelerated completion timeline of early Q4 2026, three months ahead of schedule.
The company presented outstanding feasibility data at HRS, showing 100% freedom from AF at six months and 96% at one year, with a 90% Kaplan-Meier estimated freedom from recurrent atrial arrhythmias and a low 1.7% serious adverse event rate.
Physician enthusiasm is high, with multiple sites performing five to seven cases per day and initial ablation times of seven to eight minutes, demonstrating significant workflow and procedure speed advantages over existing technologies.
Pulse Biosciences Inc (PLSE) strengthened its balance sheet, raising $57.5 million in net proceeds through its ATM program, ending Q2 with over $100 million in cash and extending its runway through key clinical and regulatory milestones.
The company is advancing multiple programs, including the surgical clamp (with 94% pulmonary vein isolation success at three months) and the Vibrance thyroid system (with a new partnership with the Clayman Thyroid Center and a 74% reduction in nodule volume), while progressing toward CE mark submissions.
Management confirmed ongoing partnership discussions with established electrophysiology players, which could support a robust go-to-market strategy for the EP catheter upon approval.

Negative

Pulse Biosciences Inc (PLSE) continues to incur significant operating losses, with GAAP net loss widening to $24.7 million in Q2 2026, up from $19.2 million in the prior year period, driven by increased clinical and employee-related expenses.
The company amended its pivotal study protocol to increase the enrollment target by 19 patients (from 145 to 164) and broaden AAD inclusion criteria, which could introduce additional statistical complexity and potentially dilute the efficacy signal.
The company's reliance on a limited number of high-performing clinical sites, which are subject to a 15% enrollment cap, creates a risk of enrollment slowdown as these sites reach their limits and new sites need to ramp up.
The timeline for regulatory approval remains lengthy, with CE mark approval for the cardiac catheter not expected until mid-2027 and US PMA approval likely dependent on 12-month follow-up data, which could extend the path to commercialization.
The company's revenue generation remains minimal, with Vibrance disposable sales of only $434,000 in Q2, indicating that the commercial launch is still in very early stages and far from achieving meaningful scale.
The company's strategy of raising capital through ATM programs, while successful, has resulted in significant dilution for existing shareholders, and the need for continued financing could pressure the stock price.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PLSE.OQ - Pulse Biosciences Inc
Q2 2026 Pulse Biosciences Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. My name is Tina and I will be your conference operator today. At this time, I would like to welcome everyone to the Pulse Biosciences Q2 2026 earnings call.

All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. To ask a question, simply press star one on your telephone keypad. To withdraw your. Question, press *1 again.

We do ask that you limit questions to one and one follow-up.

It is now my pleasure to turn the call over to Tripp Taylor, Investor Relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.